- Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its ...

Want Diversified Upside in Biotechnology? Check out LABU Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

We are here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover Pharma and Biotech here, and I am joined by CEO, Chris Anzalone of Arrowhead ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Update on REDEMPLO® Launch Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) launched REDEMPLO (plozasiran) as a treatment for adults suffering ...

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.

Fri, September 5, 2025 at 11:44 AM UTC For reference, the TRiM platform is a key part of the investment case for the stock. Arrowhead's therapies trigger ribonucleic acid (RNA) interference mechanisms ...

Are you looking for stocks that can make dramatic moves in a short amount of time? If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR). SVB Securities, a subsidiary of SVB ...

- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five ...